Overview
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility
Key Inclusion Criteria:
- Age 18-80 years
- Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
- Additional inclusion criteria are defined in the protocol
Key Exclusion Criteria:
- History of thymic surgery within 6 months of screening
- History of malignancy within the last 5 years
- Additional exclusion criteria are defined in the protocol
Other protocol defined Inclusion/Exclusion criteria will apply.
